High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors
- PMID: 21212410
- DOI: 10.1158/0008-5472.CAN-10-3018
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors
Abstract
Proteasome inhibitors such as bortezomib exhibit clinical efficacy in multiple myeloma, but studies in acute myeloid leukemia (AML) have been disappointing to date. The apparent failure in AML likely reflects a lack of biological understanding that might clarify applications of proteosome inhibitors in this disease. Here we show that AML cells are considerably less sensitive than control noncancerous cells to bortezomib-induced cytotoxicity, permitting most bortezomib-treated AML cells to survive treatment. We traced reduced bortezomib sensitivity to increased basal levels of nuclear Nrf2, a transcription factor that stimulates protective antioxidant enzymes. Bortezomib stimulates cytotoxicity through accumulation of reactive oxygen species (ROS) but elevated basal levels of nuclear Nrf2 present in AML cells reduced ROS levels, permitting AML cells to survive drug treatment. We further found that the Nrf2 transcriptional repressor Bach1 is rapidly inactivated by bortezomib, allowing rapid induction of Nrf2-regulated cytoprotective and detoxification genes that protect AML cells from bortezomib-induced apoptosis. By contrast, nonmalignant control cells lacked constitutive activation of Nrf2, such that bortezomib-mediated inactivation of Bach1 led to a delay in induction of Nrf2-regulated genes, effectively preventing the manifestation of apoptotic protection that is seen in AML cells. Together, our findings argue that AML might be rendered sensitive to proteasome inhibitors by cotreatment with either an Nrf2-inhibitory or Bach1-inhibitory treatment, rationalizing a _targeted therapy against AML.
©2011 AACR.
Similar articles
-
Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.Hemoglobin. 2014;38(3):188-95. doi: 10.3109/03630269.2014.898651. Epub 2014 Mar 26. Hemoglobin. 2014. PMID: 24670032 Clinical Trial.
-
Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013. PLoS One. 2013. PMID: 23936317 Free PMC article.
-
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.Haematologica. 2008 Jan;93(1):57-66. doi: 10.3324/haematol.11666. Haematologica. 2008. PMID: 18166786
-
Inhibiting BTB domain and CNC homolog 1 (Bach1) as an alternative to increase Nrf2 activation in chronic diseases.Biochim Biophys Acta Gen Subj. 2022 Jun;1866(6):130129. doi: 10.1016/j.bbagen.2022.130129. Epub 2022 Mar 12. Biochim Biophys Acta Gen Subj. 2022. PMID: 35292311 Review.
-
Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic _target.Onco_target. 2015 Mar 20;6(8):5490-500. doi: 10.18632/onco_target.3545. Onco_target. 2015. PMID: 25823927 Free PMC article. Review.
Cited by
-
BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors.Bioessays. 2018 May;40(5):e1800007. doi: 10.1002/bies.201800007. Epub 2018 Mar 30. Bioessays. 2018. PMID: 29603290 Free PMC article. Review.
-
Role of nuclear factor (erythroid-derived 2)-like 2 in the age-resistant properties of the glaucoma trabecular meshwork.Exp Ther Med. 2017 Jul;14(1):791-796. doi: 10.3892/etm.2017.4543. Epub 2017 Jun 2. Exp Ther Med. 2017. PMID: 28673001 Free PMC article.
-
Cytoprotection "gone astray": Nrf2 and its role in cancer.Onco _targets Ther. 2014 Aug 26;7:1497-518. doi: 10.2147/OTT.S36624. eCollection 2014. Onco _targets Ther. 2014. PMID: 25210464 Free PMC article. Review.
-
Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression.Cell Cycle. 2013 Jul 1;12(13):2144-53. doi: 10.4161/cc.25251. Epub 2013 Jun 11. Cell Cycle. 2013. PMID: 23759586 Free PMC article.
-
Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.Cell Commun Signal. 2024 Feb 8;22(1):105. doi: 10.1186/s12964-023-01433-5. Cell Commun Signal. 2024. PMID: 38331801 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous